Replimune REPL
NASDAQ REPL
$11.99 +0.27 (+2.30%)
At close: Oct 22, 2026 · 4:00 PM EDT

Replimune (REPL) Return on Sales [ROS] (2017 - 2018)

Updated

Analysis

Replimune (REPL) Return on Sales [ROS] (2017 - 2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn 51.16%
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn 24.35%
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn 37.86%
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn -3.52%
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn 32.97%
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn 20.57%
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn 34.95%
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn -133.21%
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn 28.37%
10 Replimune 1.14 Bn 79.22 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2018 -1,149.32%
Sep 30, 2018 -1,069.88%
Jun 30, 2018 -2,589.87%
Dec 31, 2017 -14,787.50%
Sep 30, 2017 -42,560.00%
Jun 30, 2017 -10,586.67%
API Access

Replimune Return on Sales [ROS] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-sales-%5Bros%5D&ticker=REPL&period=max&api_key=YOUR_API_KEY